Chong Kun Dang Pharmaceutical
Clinical trials sponsored by Chong Kun Dang Pharmaceutical, explained in plain language.
Pharmaceutical company producing prescription drugs and healthcare products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cheaper psoriasis drug on the horizon? new biosimilar enters human trials Results expected Sep 2026 (estimated)
- Can a new blood pressure pill match the original? Results expected Oct 2026 (estimated)
- New biosimilar aims to offer cheaper eczema treatment Results expected Nov 2026 (estimated)
- New hope for advanced cancer patients: experimental drug CKD-512 enters human trials Results expected Mar 2027 (estimated)
- New drug combo for BRCA ovarian cancer enters early testing Results expected Jun 2027 (estimated)
-
Can a Four-Times-a-Year injection regrow hair in men?
Disease control Recruiting nowThis phase 3 trial tests an investigational drug called CKD-843 in men aged 18 to 50 with androgenetic alopecia, commonly known as male pattern baldness. Participants receive either CKD-843, a placebo, or the existing oral medication dutasteride for 12 months. Researchers measure…
Phase 3 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Smart drug delivers chemo directly to cancer cells in new trial
Disease control Recruiting nowThis study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…
Phase 1/2 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for advanced cancer patients: experimental drug CKD-512 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participa…
Phase 1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New biosimilar aims to offer cheaper eczema treatment
Disease control Recruiting nowThis early-stage trial tests a new drug called CKD-706, which is a biosimilar (a close copy) of the approved eczema treatment Dupixent. The study involves 519 healthy adults who will receive a single injection of either CKD-706, the US version of Dupixent, or the European version…
Phase 1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Cheaper psoriasis drug on the horizon? new biosimilar enters human trials
Disease control Recruiting nowThis Phase 1 trial tests a new biosimilar called CKD-704, which is designed to be a more affordable copy of the psoriasis drug Skyrizi (risankizumab). The study involves 213 healthy adults who will receive a single dose of either CKD-704, the EU-approved Skyrizi, or the US-licens…
Phase 1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New blood pressure combo pill aims to beat standard treatment
Disease control Recruiting nowThis phase 3 trial tests whether a combination pill containing sacubitril and valsartan (CKD-202A) works better than valsartan alone for essential hypertension. About 324 adults with high blood pressure will take either the combo or the standard drug for 10 weeks. The main goal i…
Phase 3 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC